<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859079</url>
  </required_header>
  <id_info>
    <org_study_id>TCW-GLP1-1</org_study_id>
    <nct_id>NCT00859079</nct_id>
  </id_info>
  <brief_title>Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients</brief_title>
  <official_title>Efficacy of a Continuous GLP-1 Infusion in Comparison to a Structured Insulin Infusion Protocol to Reach Normoglycemia in Non-Fasted Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigators study was to compare for the first time efficacy and safety of
      intravenously administered GLP-1 with an established intravenous insulin regimen in
      hyperglycaemic type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention studies in patients with acute myocardial infraction or cardiac surgery, using
      intravenously administered human insulin, suggest that normalization of hyperglycemia can
      reduce morbidity as well as mortality in these patients. Insulin-based regimens require
      frequent blood glucose measurements and adjustments of infusion rate to achieve
      normoglycemia.

      In addition, hypoglycaemia is a frequent and important side effect. Glucagon-Like-Peptide 1
      (GLP-1) is an insulinotropic, glucagonostatic gastrointestinal hormone that lowers glucose in
      a glycemia-dependent manner and therefore does not cause hypoglycemia.

      The aim of our study was to compare for the first time efficacy and safety of intravenously
      administered GLP-1 with an established intravenous insulin regimen in hyperglycaemic type 2
      diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to reach a plasma glucose below 115 mg/dl</measure>
    <time_frame>0,30,60,120,150,180,210,240,270,300,330,360,390,420,450,480,510 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma glucose after 2 and 4 hours as well as maximum glycemia</measure>
    <time_frame>0,30,60,120,150,180,210,240,270,300,330,360,390,420,450,480,510 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hypoglycaemic episodes</measure>
    <time_frame>0,30,60,120,150,180,210,240,270,300,330,360,390,420,450,480,510 min</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenously administered GLP-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin intravenously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin intravenously according to the Munich registry</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.</description>
    <arm_group_label>GLP-1</arm_group_label>
    <other_name>GLP-1 infusion (CLINALFA, Laeufelingen, Switzerland)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human regular insulin intravenously</intervention_name>
    <description>Human regular insulin intravenously according to the Munich-registry.</description>
    <arm_group_label>Insulin intravenously</arm_group_label>
    <other_name>Insulin Actrapid, NovoNordisk, Denmark</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Fasting glycemia above 150 mg/dl

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients with heart failure &gt; NYHA II

          -  Uncontrolled hypertension

          -  Impaired kidney function (creatinine &gt; 3 mg/dl)

          -  Acute infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C Wascher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Dept. of Internal Medicine, Auenbruggerpl. 15, 8036 Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Department for Internal Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>March 9, 2009</last_update_submitted>
  <last_update_submitted_qc>March 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Thomas Wascher</name_title>
    <organization>Medical University of Graz</organization>
  </responsible_party>
  <keyword>diabetes mellitus type 2, GLP-1, insulin infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

